Octreotide

• A randomized, placebo-controlled trial to evaluate the safety and efficacy of Debio 4126 in patients with acromegaly previously treated with… Recruiting
  2024-516616-24-00 Phase III 16 countries Debiopharm International S.A.
• Study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients with Grade 1 and Grade 2 advanced GEP-NET (NETTER-3) Recruiting
  2024-518325-15-00 Phase III 7 countries Novartis Pharma AG
• Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects wi… Recruiting
  2023-509334-19-00 Phase III 4 countries Rayzebio Inc.
• Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with long-acting Somatostatin Analogues – ATSA trial Recruiting
  2023-505884-35-00 Phase IV 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• Efficacy and safety of octreotide in laparoscopic hepatectomy surgery: effect on blood loss, need for vasoactive drugs, transfusion requirem… Recruiting
  2023-503613-29-00 Phase II 1 country University Clinic Of Navarra
• Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial) Recruiting
  2022-502703-30-00 Phase IV 2 countries Antwerp University Hospital
• A trial to assess efficacy and safety of octreotide subcutaneous depot in patients with GEP-NET Ended
  2023-508723-12-00 Phase III 8 countries Camurus AB
• A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in combination with best supportive … Ended
  2023-507443-10-00 Phase III 5 countries Advanced Accelerator Applications
• Octreotide treatment to improve nutritional recovery after surgery for patients with esophageal or gastric cancer, a prospective randomized … Ended
  2022-502745-98-00 Phase II 1 country Karolinska University Hospital

Showing 1–9 of 9 trials